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A genetic diagnosis of autosomal-dominant polycystic kidney disease (ADPKD) is challenging
due to allelic heterogeneity, high GC content, and homology of the PKD1 gene with six pseu-
dogenes. Short-read next-generation sequencing approaches, such as whole-genome sequenc-
ing and whole-exome sequencing, often fail at reliably characterizing complex regions such as
PKD1. However, long-read single-molecule sequencing has been shown to be an alternative strat-
egy that could overcome PKD1 complexities and discriminate between homologous regions of
PKD1 and its pseudogenes. In this study, we present the increased power of resolution for com-
plex regions using long-read sequencing to characterize a cohort of 19 patients with ADPKD. Our
approach provided high sensitivity in identifying PKD1 pathogenic variants, diagnosing 94.7% of
the patients. We show that reliable screening of ADPKD patients in a single test without inter-
ference of PKD1 homologous sequences, commonly introduced by residual amplification of PKD1
pseudogenes, by direct long-read sequencing is now possible. This strategy can be implemented
in diagnostics and is highly suitable to sequence and resolve complex genomic regions that are of
clinical relevance.
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1 INTRODUCTION
DNA sequencing technologies have widely been applied in biomedical
and biological research as well as diagnostics. Relatively low-cost and
high-throughput are major advantages of next-generation sequenc-
ing (NGS) over standard diagnostic assays (Mardis, 2013; Oliver,
Hart, & Klee, 2015; Su et al., 2011). However, despite widespread
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
c© 2017 The Authors.HumanMutation published byWiley Periodicals, Inc.
use of NGS-based diagnostics strategies (Chang & Li, 2013; Codina-
Solà et al., 2015; Dewey et al., 2014; LaDuca et al., 2014; Ligt
et al., 2012; Ozsolak & Milos, 2011; Sun et al., 2015; von Kanel
& Huber, 2013; Willig et al., 2015; Yang et al., 2013), short-read
sequencing approaches such as whole-genome sequencing (WGS)
and whole-exome sequencing (WES), often fail at reliably charac-
terizing complex regions of the human genome (Chaisson et al.,
HumanMutation. 2017;38:870–879. wileyonlinelibrary.com/journal/humu 870
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2015; Lee & Schatz, 2012). These regions are often associated with
extreme GC content, segmental duplications (SDs), low-complexity
sequences, and gaps in the human reference sequence (Chaisson
et al., 2015; Lee & Schatz, 2012; Steinberg et al., 2014). Single-
molecule long-read sequencing can improve our understanding of
genetic variations in complex but clinically relevant genomic regions
(Guo et al., 2013; Laver et al., 2016; Loomis et al., 2013; Qiao et al.,
2016).
In this study, we aim to show the value of single-molecule long-
read sequencing as a tool to characterize genetic variants associated
with autosomal-dominant polycystic kidney disease (ADPKD). ADPKD
is a common inherited disease that accounts for 5%–10% of end-stage
renal disease (Harris & Rossetti, 2010; Spithoven et al., 2014). Most
ADPKD pathogenic variants occur in PKD1 (MIM# 601313) and PKD2
(MIM# 173910) genes with a reported prevalence of 85% and 15%,
respectively (Barua et al., 2009;Harris &Rossetti, 2010). Themutation
spectrums in PKD1 and PKD2 are highly heterogeneous, with nomuta-
tion hotspots present, indicating that pathogenic variants in either
PKD1 or PKD2 are usually private (Gout, Martin, Brown, & Ravine,
2007; Harris & Rossetti, 2010). The screening of PKD1 is challenging
due to difficulties in amplification and low resolution of its complex
locus (Qi et al., 2013;Rossetti et al., 2007; Tanet al., 2009). This is partly
due to its high homology for most of PKD1 sequence with six pseudo-
genes as well as high GC content (Qi et al., 2013; Rossetti et al., 2007;
Tan et al., 2009). In this study, we used PKD1 as an excellent example of
a challenging and complex locus.
Several attempts have been made to improve the screening of
PKD1 gene by using short-read NGS approaches to replace the stan-
dard diagnostics based on Sanger sequencing and multiplex ligation-
dependent probe amplification (MLPA) assays (Eisenberger et al.,
2015;Mallawaarachchi et al., 2016;Qi et al., 2013;Rossetti et al., 2012;
Tan et al., 2014; Trujillano et al., 2014). These strategies provided a
clear diagnosis with high sensitivity and specificity (97%–100%) for
115 out of 183 (Rossetti et al., 2012), 16 out of 25 (Tan et al., 2014), 10
out of 12 (Trujillano et al., 2014), 35 out of 55 (Eisenberger et al., 2015),
and 24 out of 28 (Mallawaarachchi et al., 2016) screened ADPKD
patients. Duplicated and high GC content genomic regions, such as
that of PKD1 gene, can lead to ambiguous identification of variants
when analyzed with short-read NGS strategies (Lee & Schatz, 2012).
These ambiguities produced low true-positive variant detection rates
of 28%–50% for the duplicated region of PKD1 (Qi et al., 2013), and
many false positives (10%) due to misalignments, low-quality align-
ments, and contamination by residual amplification of pseudogenes
(Rossetti et al., 2012). Hence, diagnostic assays based on NGS short
reads (e.g., Sanger or Illumina) may not be fully suited for reliable
ADPKD diagnostics.
Here, we utilized the single-molecule long-read Pacific Biosciences
RSII (PacBio) sequencing technology to assess its potential value
in molecular diagnostics of ADPKD patients. We show that direct
sequencing of long-range PCR (LR-PCR) products eliminates the inter-
ference of residual amplification of PKD1 pseudogenes, as well as
alignment ambiguities. This also enabled a reliable identification of
pathogenic variants, from single-nucleotide variants (SNVs) to large
deletions.
2 MATERIALS AND METHODS
2.1 Selection of subjects andDNA isolation
Nineteen genotyped patient sampleswere selected for this study from
the diagnostic laboratory in which at least one pathogenic mutation
was detected by Sanger sequencing or MLPA. The selection aimed to
includedifferent typesof variants (e.g., SNVs, aswell as small and larger
insertions and deletions [indels]) that are located in exons or in imme-
diately flanking intronic sequences, for both the duplicated regions
as well as the unique part of PKD1. Although PKD2 is not a complex
gene and is not the focus of this study, the sequencing of LR-PCR frag-
ments for PKD2 was performed as a proof of principle of long-read
sequencing and detection of variants also for PKD2. GenomicDNA iso-
lationwas performed fromperipheral blood samples usingPUREGENE ۛ
nucleic acid purification chemistry on the AUTOPURE LS 98 Instru-
ment (Qiagen).
2.2 Long-read sequencing and variant identification
for ADPKD genes
2.2.1 LR-PCR amplification
To cover the entire PKD1 and PKD2 coding regions (including exon
boundaries), a total of five and nine LR-PCR fragments were designed,
respectively. Primers were optimized to produce amplicons of similar
sizes (>4Kb) that could bepooled to improve sequencing efficiency and
loading capacity for SMRT sequencing (Supp. Table S1; Supp. Fig. S1).
The major part of PKD1 intron 1 was excluded from the design due to
its large size and the lack of previously reported pathogenic variants
in this region. Fragments were amplified from 50 ng of genomic DNA
using 1× Extensor ۛ Hi-Fidelity Long Range PCR Master Mix (Thermo
Scientific,Massachusetts, USA) on a 25𝜇l of PCR reaction volumewith
200nMofM13-taggedprimers. Initial denaturationwasperformed for
10 min at 98°, followed by 35 cycles of 15 sec at 98° and 10 min at
68°, respectively. Final extensionwas10min at 68°. Productswere size
selected using the BluePippin DNA size selection system to classify
them in three different groups of sizes 4.3–6.1, 7.1–7.5, and 7.6–8.1
Kb (Supp. Table S1; Supp. Fig. S1). Fragments of equal size were pooled
equimolar, and were visually inspected by band intensity on agarose
gel. Finally, all pools were purified with a 0.6× v/v ratio of AMPure XP
Beads (Beckman-Coulter,Woerden, Netherlands).
2.2.2 SMRT sequencing library preparation
Sample indexes for patient tracking were added to the LR-PCR frag-
ments using an additional five-cycle PCR with the previous LR-PCR
conditions. Barcoded poolswere then purifiedwith AMPure XPBeads,
and pooled equimolar according to their size.Molar concentrationwas
verified on a Bioanalyzer 12000 chip (Agilent, California, USA). For
each barcoded pool, a SMRT-bell library was prepared according to
the PacBio’s 5- or 10-Kb Template Preparation procedures. Pooled
amplicons were sequenced on five SMRT cells on the PacBio RSII sys-
tem with the P6 sequencing chemistry. Data collected from 360-min
movie timewaspreprocessedusing the standardprimaryanalysis tools
(Fig. 1).
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F IGURE 1 Flowchart of the applied analytical approach for the identification of potentially pathogenic variants and VUCS in ADPKD patient
samples. Key processes in theworkflowdescribe details and thresholds used for (1) sequencing of pooled LR-PCR amplified fragmentswith PacBio
RSII and postprocessing of reads including alignments and read quality filters; (2) identification of variants using two independent strategies includ-
ing the reconstruction of allelic sequences, and small variant calling using Quiver; (3) standardization of variant nomenclature to represent a cor-
rect HGVS description and facilitate the comparison between datasets; (4) enrichment of variant annotations with VEP (including effect predic-
tion, ClinVar, SIFT, PolyPhen, 1000 Genomes Project, dbSNP, and SwissProt annotations among others), and selection of high-confidence variants;
(5) identification of potentially pathogenic variants and VUCS based on their confidence, effect prediction, and population frequencies
2.2.3 Sequence alignment and variant calling
We used the RS_Resequencing protocol from SMRT Analysis Suite
v.2.3 to align long reads against the human reference genome, down-
loaded from the Genome Reference Consortium version 37 patch 13
(GRCh37.p13). Samples were demultiplexed into individual files (H5
and BAM formats) using known barcode sequences and a minimum
barcode identity score of 22 (Fig. 1). Alignments were filtered to con-
tain mapped reads with a mapping quality threshold of 30 Phred score
using Samtools v.1.2 (Supp. Table S2). Read coverage and targeted
PCR statistics for LR-PCR amplicons were computed with BedTools
v.2.25.0, and PicardTools v.1.1.40 (Supp. Tables S2–S4). Variant calling
was performed usingQuiver (allowing for diploid calling andmaximum
coverage of 10,000). Variants with a Quiver confidence score lower
than 40were filtered out from downstream analysis (Fig. 1).
2.2.4 Reconstruction of allelic sequences
PKD1 and PKD2 allelic sequences were reconstructed using the Long
Amplicon Analysis available in SMRT Analysis Suite 2.3. Only reads
longer than 3,000 base pairs (bp) and average signal to noise ratio
of three were used for the reconstruction (Fig. 1). Based on this
reference-free subread (full-length and nonfull-length reads) cluster-
ing, chimeric sequences were identified and comprehended ≤0.85%
(6,288/738,822) of subreads that were subsequently removed from
the analysis. Allelic sequences of PKD1 and PKD2 were aligned to
the human reference genome GRCh37.p13 using BLASR (Chaisson &
Tesler, 2012), and reporting a single best-scoring alignment. Variants
were extracted by comparison between the reconstructed alleles and
the human reference sequence with the Variant Description Extractor
from theMutalyzer Suite 2.0.21 (Vis, Vermaat, Taschner, Kok, & Laros,
2015).
2.2.5 Loss of heterozygosity analysis
Loss of heterozygosity (LoH) for each amplified fragmentwas assessed
to identify patients with potential large deletions for PKD1. We first
identified heterozygous substitutions within the amplified fragments
with a variant frequency between 25% and 75%. Amplified fragments
with zero heterozygous substitutions were identified as LoH. Large
deletions produce multiple LR-PCR fragments dropouts, and were
identified by the detection of consecutive LoH fragments. The detec-
tion of consecutive LoH fragments was not a direct identification of
large deletions per se, rather than an indication of the presence of large
deletions in the amplified LR-PCR fragment regions. Identified LoH
regions were then comparedwith large deletions detected byMLPA.
3 ADPKD VARIANT NOMENCLATURE AND
GENOTYPING
Variant descriptions were standardized to concord with HGVS guide-
lines (denDunnenet al., 2016), using theMutalyzerNameChecker tool
(Wildeman, vanOphuizen, Dunnen, & Taschner, 2008). GenomicHGVS
descriptions were converted to coding notations using the Position
Converter from Mutalyzer (Wildeman et al., 2008). Only changes in
RefSeq-annotated canonical transcripts for PKD1 (NM_001009944.2)
and PKD2 (NM_000297.3) were further analyzed. HGVS descriptions
of deletion–insertions (delins) were manually inspected to avoid vari-
ant redundancies andundesired clusteringofneighboring independent
events (Fig. 1; Supp. Table S5). Then, standardized variants were anno-
tated using theVariant Effect Predictor (VEP), fromEnsembl tools v.83
(McLaren et al., 2010), with additional parameters “-everything,” and
“-refseq” (Fig. 1). All variant annotations reported by VEP are fully dis-
closed in the raw VCF files (EGAS00001002106). Variant frequency
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and coverage were used to filter low-confidence variants by apply-
ing thresholds for: (1) sequencing depth of ≥50× subreads and ≥15×
reads that ensures a sufficient control over the SMRT sequencing ran-
dom error rate (1% mismatches and 13% indels) and (2) minimum
variant frequency of 10% for substitutions and 15% for delins (Fig. 1).
For interpreting insertion and deletion frequencies, neighboring bases
were also examined. The selection of strong pathogenic variant candi-
dates or variants of unknown clinical significance (VUCS)was based on
the following criteria: (1) high predicted effect on the coding sequence
or splice-site region (e.g., missense, in-frame indels, frameshifts, and
splice-site acceptor or donor variants); (2) population frequency in the
1000 genomes project <1%; (3) unique occurrence (1/19) (∼5%) in
the patient cohort since, in ADPKD, no single disease-causing vari-
ant accounts for more than 2% of affected families (Harris & Rossetti,
2010), or more than 1.7% of ADPKD reported cases in the ADPKD
database (PKDB) (http://pkdb.mayo.edu/; accessed version 3.1) (Gout
et al., 2007) (Fig. 1).
3.1 Clinical diagnostics pipeline for ADPKD
genotyping
3.1.1 Sanger sequencing
The current diagnostics pipeline for ADPKD genotyping, including
Sanger sequencing and MLPA, uses a different set of LR-PCR primers
to target the duplicated part of PKD1 (exons 1–32) (Supp. Table S6).
The nonduplicated region of PKD1 (exons 33–46), and PKD2 regions
(exons 1–5) were amplified using targeted standard PCR reactions
(Supp. Fig. S1), with 100 ng of input genomic DNA with M13 tail
primers. The nested and standard PCR amplicons were designed to
cover the complete coding regions and splice sites with at least 20
bp of flanking intronic sequences (Supp. Tables S7 and S8). The dupli-
cated part of PKD1, which includes exons 1–32, was amplified using
four different LR-PCR fragments that covered exons 1, 2–13, 14–21,
and 22–32, respectively (Supp. Table S6). LR-PCR amplification was
performed using Thermo Scientific (Massachusetts, USA) 2× Exten-
sor Long Range PCR Master Mix on 50 ng of DNA. Then, a nested
PCR was carried out on 4 𝜇l 100–250× of diluted product to obtain
the final Sanger sequencing fragments. The nested PCR primers with
an M13 tail were used to amplify the coding region including 5–20
bp of intronic sequences (Supp. Fig. S1). Large exons such as exon 5,
10, 11, 15, and 23 were amplified using overlapping nested PCR prod-
ucts, although 10 bases of exon 15 (c.6503-6514) were not covered.
Nested PCR and standard PCR of the nonduplicated part of PKD1, and
PKD2, was carried out in a final volume of 15 𝜇l in GoTaq Colorless Taq
Reaction buffer with 0.6 U of Taq DNA polymerase (Promega, Leiden,
Netherlands) at a final concentration 5 pM for each primer, 200 𝜇Mof
each dNTP. After a hot start at 95°C, a denaturation was performed
for 5 min at 95°C, followed by 35 cycles of 45 sec at 94°C, 45 sec at
60°C, and 30 sec at 72°C. The final extension was of 5 min at 72°C in
a T-Professional Thermocycler (Biometra, Göttingen, Germany;West-
burg, Leusden, Netherlands). All liquid handling steps were automated
using the SciClone (ALH-HV96 pipetting station; Perkin Elmer, Mas-
sachusetts, USA) or Biomek FX workstation (Beckman-Coulter, Woer-
den, Netherlands). PCR products (20–50 ng) were purified using an
Ampure XP PCR purification kit and sequenced using BigDye Ter-
minator v3.1 sequencing reactions (Applied Biosystems, California,
USA) with PAGE purified –21M13 orM13REV sequencing primer. The
excess of dye terminatiorswas removed by gel filtration using the Edge
Biosystem Dye Terminator Removal (DTR) with a 96-well plate. After
electrophoresis on an ABI Prism 3730 (XL) DNA analyzer (Life tech-
nologies, California, USA; Applied Biosystems, California, USA), data
processing was automated using SeqPatient software (Sequence Pilot,
JSIMedical Systems GMbH, Ettenheim, Germany).
3.1.2 MLPA
To detect large deletions and duplications, two commercially avail-
able MLPA kits (P351-B2 and P352-C1; MRC-Holland, Amsterdam,
The Netherlands) were used following manufacturer’s protocols and
manuals.
3.2 Comparative analysis of SMRT sequencing and
current ADPKDdiagnostic assay
The overlap between identified variants based on PacBio and Sanger
sequencing data was achieved by assessing identical standardized
HGVS descriptions. Only variants with predicted effects on coding
DNA or splice-site regions were considered (Supp. Table S5). PacBio
and Sanger variants were manually inspected to detect overlapping
variants with discordant descriptions between the two datasets. To
facilitate interpretation, each unique variant was further annotated
with its PKDB clinical significance, single-nucleotide polymorphism
database version 144 (dbSNP) identifier, and the number of patients
where it was detected in the cohort. Surrounding bases were evalu-
ated to identify and remove potential sequencing artifacts occurring
in homopolymer stretches. Finally, variants were considered as high-
confident variants if previously reported in PKDB or dbSNP, showed
strongPacBio sequencing evidenceof beingpresent, or detected in any
patient by both Sanger and PacBio sequencing.
3.3 Short-read loss of power for known PKD1
pathogenic variants inWGS andWES
Previously known pathogenic variants for PKD1 gene were obtained
from PKDB. Only variants that were classified as “definitely
pathogenic” were selected for further analysis. Large deletions
(few hundred bp to several Kbp long) were excluded from the anal-
ysis as they are not usually detected with common variant calling
algorithms. For the genomic position of each pathogenic variant,
sequencing depth was extracted from nine publicly available WGS
and WES datasets (Sun et al., 2015). In addition, we included the
sequencing depth of nine randomly selected libraries from the study
of Rossetti et al. (2012), in which the authors used a similar strategy
based on LR-PCR and followed by short-read sequencing. Each library
represents an equimolar pool of DNA from four different patient sam-
ples that were not possible to further demultiplex because individuals
were not barcoded. Variant positions with low sequencing depth (<8
reads, or <32 for the short-read LR-PCR approach) were marked as
inaccessible positions of clinical significance using BedTools v2.25.0.
Finally, variant positions were classified into three categories based
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F IGURE 2 SMRT sequencing and variant calling of LR-PCR amplicons. A: Sequencing depth (DP; in number of reads) of the alignments to chro-
mosome 16 and chromosome 4. Number of uniquely aligned reads (y axis, blue line) sequenced with PacBio that mapped to PKD1 and PKD2. Off-
target amplification is discriminated from the main PKD1 gene sequences showing alignments to pseudogene homologous sequences at proximal
loci (e.g., PKD1P1, PKD1P5, PKD1P6) (blue boxes). B: Mapping quality (MQ; in Phred quality scores; values >90 were scaled down for visualization
purposes), and sequencing depth (DP; in number of reads) of uniquely aligned molecules to PKD1 (NM_001009944.2) for the five LR-PCR frag-
ments amplified. Mapping quality of alignments with even coverage distribution along the amplified fragments (fragments), including regions with
SDs, repetitive elements (repeats), and high GC content (GC%). Despite fragments A and E showing lower coverage, compared with the average
sequencing depth of≥421× (minimum ≥19×; maximum 1,528×), they had sufficient coverage for variant calling within the exon regions, including
the first exons of PKD1, with average coverage of ≥55× (minimum ≥24×; maximum 91×) (Supp. Table S4). C: We detected 1,506 intron variants
(blue) and 177 coding or splice-site variants (yellow). The predicted transcript effects of coding and splice-site variants were quantified (bar chart)
as log10 count (x axis)
on the number of individuals with poor coverage at each position: (1)
variants with sufficient coverage in all nine individuals; (2) variants
reported inaccessible in two to four individuals; and (3) variants
reported inaccessible in five ormore individuals.
3.4 Data availability
Sequencing data and alignments in BAM format can be accessed
through the European Genome-phenome Archive (EGA), as well as
raw variants in VCF file format, under the EGA study identifier
EGAS00001002106.Coding or splice-site variantswere also uploaded
to the LeidenOpenVariationDatabase (LOVD). Description and exam-
ples of custom scripts used in this manuscript are accessible upon
request from a local GitLab repository.
4 RESULTS
4.1 Targeted sequencing of ADPKD genes
Direct sequencing of LR-PCR fragments (designed to specifically and
uniquely amplify PKD1, and PKD2 gene regions) (Supp. Fig. S1; Supp.
Table S1) was performed to evaluate the utility of long-read sequenc-
ing in resolving ADPKD for molecular diagnostics. All PKD1 and PKD2
exons (including the duplicated part of PKD1, as well as 20 bp of flank-
ing intron regions) from 19 ADPKD patients could be completely cov-
ered using long reads, sequenced on the PacBio RSII platform (Fig. 2;
Supp. Fig. S2). Most of the long reads (94.4%) were uniquely mapped
to PKD1 and PKD2 (Supp. Table S2). Reads originating from residual
off-target amplification (5.6%; Supp. Table S2) introduced during the
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F IGURE 3 Comparison of long-read detected pathogenic variants or VUCS, uniquely identified per patient (y axis), with the screening results for
the PKD1 gene locus (x axis; NM_001009944.2).Most of the pathogenic variants (red) could be confirmed by our long-read strategy (red bars) with
high sensitivity forPKD1. Only a single insertion could not be confirmed for patient 16.Other identifiednonpathogenic variants orVUCSare shown
as black bars and dots for PacBio and Sanger, respectively. The LoH analysis performed (pink or gray boxes) support the presence of the two large
deletions also reported byMLPA (pink boxes). LoH regions are not a direct identification of large deletions but a clear indication of their presence
within the amplified LR-PCR fragments
LR-PCR stepswere identified, and discriminated, by their unique align-
ment to the PKD1 pseudogenes (Fig. 2; Supp. Table S2). All PKD1 and
PKD2 protein coding and flanking intron sequences (±20 bp)were cov-
ered at average sequencing depth ≥421× (minimum ≥19×; maximum
1,528×), with ≥97.36% of bases over ≥30×, which was well above the
applied threshold of ≥15× reads (Supp. Tables S2 and S4). Amplicons
that cover the first and last exons of PKD1 were underrepresented
when compared with other LR-PCR fragments, with a total of ≥593
average reads (minimum ≥300; maximum 1,580) and ≥87 (minimum
≥35; maximum 153) for PKD1 fragments A and E, respectively (Fig.
2B; Supp. Table S3). The usually difficult to sequence first exons of
both PKD1 and PKD2 geneswere covered, on average≥55× (minimum
≥24×; maximum 91×) and ≥71× (minimum ≥43×; maximum 111×),
respectively (Supp. Table S4). Most of the sequenced reads (>99.9%)
were uniquely mapped to PKD1 and PKD2 (Fig. 2B; Supp. Fig. S2).
4.2 Sensitive detection of ADPKD small variants
PKD1 is known to be a highly polymorphic gene with many variants
reported in addition to the disease-causing or pathogenic variants
(Gout et al., 2007). Hence, the required sensitivity to resolve PKD1
was achieved by the combination of variant calling using Quiver and
the reconstruction of amplified allelic sequences. Overall, we identi-
fied 1,683 variants (404 SNVs) across 19 ADPKD patients, fromwhich
177 variants (119 SNVs) were located in coding or splice-site regions
(Fig. 2C). Variants were distributed along PKD1 (Supp. Fig. S3A) includ-
ing regions with large SDs and high GC content. The mismatch rate
of PacBio data was empirically assessed based on average frequency
of mismatches at each position. We observed an average of 1.2% mis-
match rate across the entire PKD1 gene (Supp. Fig. S3A). This corre-
lates with the random sequencingmismatch rate of 1% for PacBio, and
thus the applied minimum frequency threshold of 10% for substitu-
tions is well above the observed noise introduced by random PacBio
errors.
4.3 Large deletions in PKD1
Detection of allele dropouts and large deletions in PKD1was assessed
by performing a LoH analysis for each of the amplified regions (Fig. 3).
We identified 17 LR-PCR fragments with LoH among all 19 patients
sequenced. Most of LoH regions (10) were identified in fragment E
(Fig. 3). Only two patients showed consecutive LoH fragments indi-
cating the presence of large deletions spanning between two or more
LR-PCR fragments. These consecutive LoH fragments are not a direct
identification of the deletions per se but an indication of the pres-
ence of large deletions in the amplified region. The two patients
that showed two or more consecutive fragments with LoH (Fig. 3)
were in concordance with large deletions identified by MLPA as
pathogenic variants in the sameADPKDpatients. A deletion of≥1,543
bp (c.(2097+1_2098-1)_3640del; exons 11–15) and a deletion of
≥9,108 bp (c.(287+1_288-1)_(9397+1_9398-1)del; exons 3–26) were
detected by MLPA for patient sample 7 and 13, respectively. With the
current experimental design, however, the exact location of the break-
points for each large deletion could not be determined with either
method.
4.4 Comparative analysis between SMRT-Seq and
the ADPKDdiagnostic assay
The evaluation of 167 coding or splice-site variants identified by stan-
dard ADPKD diagnostic assay showed that 159 out of 167 were
correctly detected by PacBio (Supp. Fig. S3C). The overall observed
sensitivity and specificity in detecting coding variants was of 95.2%
(159/167) and 88.8% (159/179), respectively. Eight variants were
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solely detected by Sanger (Supp. Fig. S3A: crosses), fromwhich, despite
the high sequencing depth, themajority (6/8) had low number of reads
supporting the presence of these variants in PacBio sequencing data
with variant frequency below the applied frequency thresholds (Supp.
Fig. S3B: yellow dots). The remaining 2/8 variants (Supp. Fig. S3B: red
dots) constitute a pathogenic insertion (c.6223_6224insTT) and one
polymorphic substitution (c.12630T>C) (Supp. Table S9; Supp. Fig. S4).
From 179 variants detected by PacBio, 20 were solely identified by
PacBio (Supp. Fig. S3C; Supp. Table S9). Of these, 17/20 were high-
confident variants not detected in Sanger. The remaining 3/20 were
low-confidence variants from the reconstruction of allelic sequences
for the variant c.6657_6671del (Supp. Table S9).
The sensitivity assessment for PKD1 pathogenic variants was
performed by comparing the list of potentially pathogenic variants
and VUCS, uniquely identified by our direct long-read sequencing
approach, with the results from the standard ADPKD diagnostic
assay. Although we expected a single dominant pathogenic variant per
patient, two of the patients had a combination of two pathogenic vari-
ants resulting in 21 PKD1 pathogenic variants. We identified 20 out of
21 pathogenic variants (95.2%) in addition to seven VUCS from which
two were uniquely detected by PacBio (Table 1; Fig. 3). Only a single
pathogenic insertion (c.6223_6224insTT) was missed by PacBio vari-
ant calling despite sufficient read support (43.3% variant frequency;
read depth 1,203) (Table 1). In summary, 18 out of 19 ADPKD patients
could be resolved by our method (Fig. 3). This provided a diagnosis for
94.7% of the patients, resulting in the correct detection of all PKD1
substitutions, single-nucleotide deletions, large deletions, one delin,
and three out of four insertions or duplications (Table 1).
4.5 Loss of PKD1 diagnostic power in short-read
(Illumina) NGS
The potential loss of diagnostic power when resolving PKD1 by short-
read NGS was evaluated based on 797 pathogenic variants that were
previously reported and validated, and are publicly available in PKDB.
The repetitive nature of PKD1 gene hampers proper alignment of
short Illumina NGS reads (Supp. Fig. S5). Over 12% of the reported
pathogenic variants would have been missed in WGS and WES data
purely due to poor sequencing depth (Supp. Fig. S6). In compari-
son, other short-read approaches based on LR-PCR enrichment show
lower percentage (1.3%) of reported pathogenic variants that would
have been missed because of low sequencing depth. However, this
approach required very high sequencing depth, which can be appreci-
ated from the observed high variability in coverage ranging from <8×
to >30,000× (Supp. Fig. S6). Moreover, several exonic regions may be
expected to be missed in many samples, irrespective of the short-read
sequencing strategy used (Supp. Fig. S6).
5 DISCUSSION
Accurate diagnosis is a difficult task when performed in complex
genetic regions such as PKD1 (Qi et al., 2013; Rossetti et al., 2007; Tan
et al., 2009). To facilitate the diagnosis, we have developed and applied
a newmethodology using direct long-read sequencing of amplified LR-
PCR fragments on PacBio. Because of the repetitive nature of PKD1,
current diagnostics is performed by Sanger sequencing using LR-PCR
fragments generated for approximately two thirds of the PKD1 gene
that serve as a template for the exon-specific nestedPCRamplification.
In contrast, in this study, we directly sequenced all LR-PCR fragments
amplified from the duplicated and unique parts of PKD1 gene aswell as
PKD2. On topof reducing thePCRamplification steps requiredand lim-
iting the implicit PCR artifacts, single-molecule sequencing improves
sequence alignments and aids in discriminating between homologous
or repeated sequences, such as PKD1 pseudogenes. This provides a
cleaner dataset for variant calling, free of chimeric (0.85%) and pseu-
dogene (5.6%; Supp. Table S2) reads that are introduced by the LR-PCR
amplification. Finally, by using this approach, we identified 20 out of 21
(95.2%) PKD1 disease-causing variants diagnosed by Sanger sequenc-
ing or MLPA, providing a correct diagnosis for 18 out of 19 ADPKD
patients (94.7%) with at least one pathogenic variant in PKD1.
In comparison to current ADPKD diagnostic assays, based on
Sanger sequencing andMLPA, we show that direct long-read sequenc-
ing can aid in resolving PKD1 for ADPKD diagnostics. Longer sequenc-
ing reads discriminate between PKD1 and pseudogenes (Fig. 2A), and
improve the mapping quality of PKD1 (Fig. 2B). The improved mappa-
bility reduced the interferenceof homologous sequences, highGCcon-
tent, or repetitive elements for ADPKD diagnosis (Qi et al., 2013). This
allowed us to develop a long-read-based sequencing assay for detect-
ing a broad spectrum of variants, from SNVs to large deletions (Table
1). In contrast, Sanger sequencing is very labor-intensive and requires
many phases of overlapping PCR amplification steps prior to sequenc-
ing, including LR-PCR and nested PCR. Despite the amplification of
PKD1 being based on unique PCR primers, these are of limited num-
ber forPKD1 andhave been shown to produce residual amplification of
homologous regions that would still interfere with the aggregated sig-
nal of Sanger sequencing (Rossetti et al., 2012; Tan et al., 2014). Based
on our approach, we confirmed the presence of residual amplification
of PKD1 pseudogenes, introduced by the LR-PCR (5.6%) (Fig. 2A; Supp.
Table S2). This, most likely, led to the identification of 24 false-positive
or false-negative variants detected by Sanger sequencing (Supp. Table
S9; Supp. Fig. S4). One of themajor drawbacks of ourmethod, however,
is the noise associated with PacBio sequencing, and the sophisticated
algorithms required to overcome it. This noise is likely to be the cause
of most of the 324 homopolymer deletion artifacts that were solely
identified by PacBio (Supp. Table S10). In addition, this noise was the
most likely cause of the single pathogenic insertion that was missed
despite ample sequencing depth. However, based on a recent release
of the new circular consensus calling algorithm for PacBio sequenc-
ing data (www.pacb.com: “An improved circular consensus algorithm with
an application to detect HIV-1 drug-resistance associated with mutations
(DRAMS)”), we expect that calling of true homopolymer-associated
variants will be significantly improved.
In recent years, several attempts have been made to replace the
standard ADPKD diagnostics by NGS approaches that would improve
the screening of PKD1 gene (Eisenberger et al., 2015;Mallawaarachchi
et al., 2016; Qi et al., 2013; Rossetti et al., 2012; Tan et al., 2014;
Trujillano et al., 2014). These screenings were based on
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analyzing WGS or WES data (Mallawaarachchi et al., 2016; Qi
et al., 2013), on the enrichment of PKD1 using LR-PCR (Rossetti
et al., 2012; Tan et al., 2014), or the hybridization capture of PKD1
(Eisenberger et al., 2015; Trujillano et al., 2014). Two of these studies
were performed on short-read NGS using targeted enrichment of
PKD1 or PKD2 genes by LR-PCR (Rossetti et al., 2012; Tan et al., 2014).
In both studies, the use of short reads was the source of difficulties
associated with misalignments and lack of sufficient coverage, such
as the PKD1 exon 1 region (Tan et al., 2014), as well as false-positive
(10%) and false-negative variant calls (5%) (Rossetti et al., 2012). We
show that these challenges were mitigated with long-read sequencing
that provided 100% coverage >10× (minimum >19×; average >421×;
maximum 1,528×) for all PKD1 and PKD2 exons and flanking intron
regions (±20 bp) (Supp. Tables S2 and S4), including 100% of PKD1
exon 1 at average coverage of >55× (±20 bp of flanking intron regions
included) (Supp. Table S4). OtherWES-based strategies were reported
to resolve only 50% of true-positive variants in the duplicated regions
of PKD1 (Qi et al., 2013). It was argued that increasing the sequencing
depth was insufficient to overcome the limitations and pitfalls of
short-read NGS approaches (Eisenberger et al., 2015; Qi et al., 2013).
Similar to these short-read NGS strategies (Eisenberger et al., 2015;
Mallawaarachchi et al., 2016; Qi et al., 2013; Rossetti et al., 2012; Tan
et al., 2014; Trujillano et al., 2014), our targeted approach combined
with multiplexed sequencing can further accelerate ADPKD diagnos-
tics, compared with the labor-intensive Sanger sequencing (Rossetti
et al., 2012; Tan et al., 2014). Despite the rather limited sample size,
sufficient numbers were included in this study for a methodology
evaluation. However, future studies including larger cohorts would
be needed to reliably implement the proposed methodology into the
clinic. In addition, our method can benefit from recent advancements
in library preparation methods with minimal or no amplification, such
as single-strand adaptor ligation (Karlsson et al., 2015), which would
eliminate most of the biases introduced during LR-PCR amplification
steps (Hestand, Houdt, Cristofoli, & Vermeesch, 2016; Laver et al.,
2016; Schirmer et al., 2015). Overall, our method provides high
sensitivity in identifying PKD1 genetic variants when compared with
the standard ADPKD diagnostic assay and showed an added value to
become a reliable alternative. In addition, the method presented here
is comparable to other Illumina short-read NGS-based approaches.
However, further studies including a larger cohort may be required to
decipher the true diagnostic power of our approach compared with
that of standard ADPKD diagnostic assays using Sanger and MLPA,
and to Illumina short-read NGS-basedmethods.
In conclusion, we showed that direct sequencing of LR-PCR frag-
ments for the screening of ADPKD patients in a single diagnostic test
application is now possible. Accurate screening of PKD1with high sen-
sitivity and low interference of homologous sequences constitutes a
clear example. This method is highly valuable for a diagnostic setting,
as it increases the resolution power of clinically relevant but difficult
to sequence or to resolve genomic regions.
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